Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A real world study of Bortezomib in Combination with Thalidomide and Dexamethasone in Stem Cell Transplant (Sct) Ineligible Multiple Myeloma (Mm) Patients

Trial Profile

A real world study of Bortezomib in Combination with Thalidomide and Dexamethasone in Stem Cell Transplant (Sct) Ineligible Multiple Myeloma (Mm) Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2018

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Thalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2018 New trial record
    • 14 Nov 2018 Results assessing Bortezomib in Combination with Thalidomide and Dexamethasone (Vtd) in Stem Cell Transplant (Sct) Ineligible Multiple Myeloma (Mm) Patients, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top